Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Expands Pipeline, Extends Cash Runway into 2013


Tekmira Pharmaceuticals this week announced that it has expanded its pipeline with the addition of an siRNA-based drug candidate for alcohol dependence.

The company separately updated its cash guidance, stating that it has enough funds to carry it into the second half of 2013.

The new drug program focuses on aldehyde dehydrogenase 2, or ALDH2, which the company said is a “key enzyme" in ethanol metabolism.

“Inhibition of aldehyde dehydrogenase 2 activity, through the silencing of ALDH2, results in the buildup of acetaldehyde,” Tekmira said. “Elevated levels of acetaldehyde are responsible for the adverse physiological effects that cause individuals to avoid alcohol consumption.”

The firm noted that it is developing its alcohol dependence drug, called TKM-ALDH2, with an exclusive license to Alnylam Pharmaceuticals' RNAi technology against the target.

Meantime, Tekmira has extended its cash runway, in part due to the impact of a recently completed $4.1 million private placement of stock and warrant units.

According to the company, each unit consists of one share and a one half of a one-share-purchase warrant. Each whole warrant entitles the holder to buy a share of Tekmira's common stock for about $2.63.

The company said it ended 2011 with cash and cash equivalents totaling $9.3 million.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.